Preliminary Observations of the Initiation and Tolerability of Sacubitril/Valsartan in Hospitalized Patients with Chronic Heart Failure
Introduction: The angiotensin receptor/neprilysin inhibitor (ARNI) sacubitril/valsartan was recently found to be superior to enalapril in the reduction of cardiovascular death and hospitalization in heart failure patients with a reduced ejection fraction (HFrEF). A run phase was required to assure tolerability of enalapril 20 mg daily and sacubitril/valsartan 200 mg BID. Hypotension eliminated some candidates during the run in phase. Historical trials have also demonstrated a substantial decrease in systolic blood pressures (SBP) with dual angiotensin receptor/neprilysin blockade compared with either class used alon e.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Kathleen M.D. Faulkenberg, J. Bradley Williams, Michael Militello, Antonio L. Perez, Randall C. Starling, W.H. Wilson Tang Source Type: research
More News: Cardiology | Cardiovascular | Diovan | Enalapril | Heart | Heart Failure | History of Medicine